MBRXA better-than-expected peek
Moleculin Biotech came out swinging with interim data from its Phase 2/3 MIRACLE trial, and the headline is simple: both Annamycin dose arms beat the control arm on the trial's primary endpoint. On a full intent-to-treat basis, complete remission rates were 43% and 36% in the two Annamycin groups, compared with just 12% for control.
That’s not a small bump. That’s the kind of difference that makes investors sit up straighter, especially in biotech where one clean data readout can change the whole mood music. The company also said composite complete remission landed at 50% and 57% in the treatment arms versus 29% for control.
Why traders care
This is still interim data, so nobody should confuse it with a victory lap. The trial is ongoing, with enrollment continuing and 67 of the 90 Part A subjects already in the books. In biotech land, that means the story is still being written—and the market will be watching whether these numbers hold up as the sample gets bigger.
The big picture
For Moleculin, this is the classic biotech two-step: first the data tease, then the market tries to price in the dream. If Annamycin keeps outperforming in relapsed or refractory AML, the company could have a much stronger case for the drug’s path forward. Big picture: in small-cap biotech, one good remission chart can do a lot of heavy lifting.